Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery have announced a strategic initiative to accelerate AI-driven small-molecule drug discovery emerging from Israel’s academic research ecosystem. Facilitated by Ramot, Tel Aviv University’s technology transfer company, the collaboration is designed to support researchers and scientific entrepreneurs working on novel disease targets. The initiative combines the Blavatnik Center for Drug Discovery’s experimental infrastructure and translational drug discovery capabilities with Evogene’s computational chemistry platform, including its ChemPass AI™ generative engine. Selected projects will receive support through an integrated design, make, test, and analyze workflow intended to help move promising biological insights toward viable drug development programs. By bringing together academic science, experimental validation, and AI-enabled molecule design, the collaboration addresses a critical gap in early-stage therapeutic innovation. The initiative reflects the Blavatnik Center’s mission to advance pioneering medical research from the laboratory toward potential patient benefit. Read the release here.